How do you dose or sequence therapy to overcome radioresistance from oligometastatic disease from RCC?

RAPPORT (NCT02855203) [Siva et al., PMID 34953600] was a phase I/II trial which used a combination of RT and pembrolizumab. RT was given with SBRT (20 Gy/1# prescribed to the 80% isodose line) or conventional radiotherapy (30 Gy/10#) when the treatment volume was in close proximity to a dose-limitin...